A no surprise budget for health in Australia

25 October 2022
australia_big-1

Pharma trade body Medicines Australia has welcomed the Anthony Albanese’s government Budget announced by Treasurer Jim Chalmers Tuesday, which takes steps towards addressing economic pressures and introduces new funding for Prescription Benefit Scheme (PBS) listings.

Medicines Australia chief executive, Elizabeth de Somer, said: "Tonight’s budget concentrates on alleviating the costs of living pressures and sets into motion election commitments. As expected, this budget is a prelude to the May budget, where we would hope to see increased investment in health innovations, medicines and technologies that improve lives and save lives."

The maximum cost of general scripts under the PBS has fallen for the first time in 75 years. From January 1, 2023, the PBS general co-payment will be lowered from A$42.50 ($27.23) to A$30 a script, saving about 3.6 million Australians A$190 million in out-of-pocket costs a year. In addition, A$1.4 billion will be provided for new and amended listings on the PBS.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical